From Biology to Therapy: The CLL Success Story
Abstract. Chemoimmunotherapy has been the standard of care for patients with chronic lymphocytic leukemia (CLL) over the last decade. Advances in monoclonal antibody technology have resulted in the development of newer generations of anti-CD20 antibodies with improved therapeutic effectiveness. In p...
Main Authors: | Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer, Daniel Mertens |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-04-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000175 |
Similar Items
-
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
by: Karol D. Urbanek, et al.
Published: (2022-12-01) -
Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01) -
P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
by: Deyan Yosifov, et al.
Published: (2023-08-01) -
Editorial: Biology and treatment of high-risk CLL
by: Eugen Tausch, et al.
Published: (2023-02-01) -
Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)